Psilocybin mitigates the cognitive deficits observed in a rat model of Fragile X syndrome.
Buzzelli V, Carbone E, Manduca A, Schiavi S, Feo A, Perederiy JV, Ambert KH, Hausman M, Trezza V
Publication record · Explore literaturePublic tracker catalogue and stored structured reference metadata. External references may have identifiers only. No live external citation lookup is performed.
References — this paper cites (0)
No references identified in the available metadata. This does not establish that none exist.
Cited by — these papers cite this paper (5)
- Long- term administration of low doses of psilocybin causes epigenetic changes in the rat medial prefrontal cortex 2026-07-28 · Expand citations
- Revealing shortcomings in the assessment of psilocybin effects on OCD-related symptoms in preclinical and clinical studies: A systematic review 2026-07-01 · Expand citations
- Company on brink takes psilocybin to trial for fragile X syndrome 2023-01-01 · Expand citations
- Going on Trial: Arbaclofen reboot; cell implants; psilocybin microdoses 2023-01-01 · Expand citations
- Going on Trial: Serotonin drug; psilocybin phase 2; placebo response data 2023-01-01 · Expand citations